Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429151 | 0.90 | CYP2C19 (0.41) | CYP2C19L3MBTL1POLBTDP1MAPT | |
| SCHEMBL6508258 | 0.83 | MAP2K1 (0.43) | CYP2C19L3MBTL1POLBMAPTALDH1A1 | |
| SCHEMBL1606025 | 0.82 | MAPT (0.46) | L3MBTL1POLBMAPTALDH1A1KMT2A | |
| SCHEMBL6427444 | 0.81 | CYP2C19 (0.41) | CYP2C19L3MBTL1POLBMAPTALDH1A1 | |
| SCHEMBL6426946 | 0.79 | P2RX7 (0.44) | CYP2C19L3MBTL1POLBMAPTALDH1A1 | |
| SCHEMBL6427367 | 0.79 | MAPT (0.37) | TDP1MAPTALDH1A1GAAKDM4E | |
| SCHEMBL6427842 | 0.79 | ALDH1A1 (0.56) | CYP2C19L3MBTL1POLBALDH1A1KMT2A | |
| SCHEMBL6426304 | 0.79 | EPHX2 (0.34) | L3MBTL1POLBTDP1ALDH1A1KMT2A | |
| SCHEMBL6502404 | 0.78 | ALDH1A1 (0.49) | CYP2C19MAPTALDH1A1KMT2AGAA | |
| SCHEMBL1606042 | 0.78 | POLB (0.44) | L3MBTL1POLBTDP1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | CYP2C19 89/4885L3MBTL1 4470/4885POLB 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.